Hereditary hemorrhagic telangiectasia (HHT) is a rare autosomal-dominant disease characterized by pathologic angiogenesis that provokes vascular overgrowth. The evidence about the influence of Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) in patients with rare diseases is scarce. We aimed to know the prevalence of coronavirus disease 2019 (COVID-19) in HHT patients. The HHT pathogenic angiogenesis and endothelial injury in COVID-19 are discussed using data from RiHHTa (Computerized Registry of Hereditary Hemorrhagic Telangiectasia) registry. RiHHTa is an open, multicenter, prospective, observational registry including adult patients with HHT. A 27-item survey that captured clinical data of admitted HHT patients for COVID-19 was distributed to all RiHHTa investigators from June 8th to June 24th 2020. Only one out of 1177 HHT patients was admitted for COVID-19 pneumonia. She is a 74 years-old woman with a pathogenic variant in ACVRL1 gene. Her clinical course did not involve mechanical ventilation or worsening epistaxis, and she was successfully discharged after two weeks. The endothelial damage and the consequent angiogenic process in COVID-19 patients deserve further investigation.

+More

June

Riera-Mestre, Antoni, Iriarte, Adriana, López-Wolf, Daniel, del Castillo, Raul, Moreno, Manuela,.Angiogenesis, hereditary hemorrhagic telangiectasia and COVID-19. (),.

Riera-Mestre, Antoni, et al."Angiogenesis, hereditary hemorrhagic telangiectasia and COVID-19"

Riera-Mestre, Antoni, Iriarte, Adriana, López-Wolf, Daniel, del Castillo, Raul, Moreno, Manuela,"Angiogenesis, hereditary hemorrhagic telangiectasia and COVID-19"